Abstract
Alzheimer Disease (AD) is a chronic neurodegenerative disease. Currently, treatment for AD is limited to symptomatic treatment only, which are cholinesterase inhibitor and memantine. Acting as a symptomatic treatment, those drugs don't act on the pathogenesis of AD. Tramiprosate is a small aminosulfate substance which able to decrease the aggregation of amyloid plaque. Currently there are plenty of studies regarding its effectiveness for the treatment of AD, yet reviews regarding this topic are still lacking to analyze the effect of tramiprosate on clinical outcomes of mild to moderate Alzheimer disease (AD) patients. A systematic review was conducted based on PRISMA through PubMed, ScienceDirect, and CENTRAL, searching for randomized controlled trials which analyze tramiprosate's effects on clinical outcomesof mild to moderate AD patients. Studies selected were then assessed for bias risk with CONSORT criteria. The search yielded six RCTs with a total of 6.346 subjects. Tramiprosate intervention is proven to be effective in reducing ADAS-cog and CBR-SB score while decreasing the decline of hippocampus volume significantly. Furthermore, there are another clinical benefit, such as increasing DAD and cognitive function that showed a positive trend. To conclude, tramiprosate showed promising results to be widely implemented as treatment for mild to moderate AD patients.
Concepts :
Citations by Year
| Year | Count |
|---|---|
| 2021 | 0 |